查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012295

抗真菌药物市场：2026-2032年全球市场预测（按药物类别、剂型、治疗领域、通路和最终用户划分）

Antifungal Drugs Market by Drug Class, Dosage Form, Therapeutic Area, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗真菌药物市场价值将达到 167.9 亿美元，到 2026 年将成长至 178.1 亿美元，到 2032 年将达到 259.3 亿美元，复合年增长率为 6.39%。

主要市场统计数据
基准年 2025 167.9亿美元
预计年份：2026年 178.1亿美元
预测年份 2032 259.3亿美元
复合年增长率 (%) 6.39%

抗真菌药物市场的策略框架，整合了临床进展、流通结构的变化和商业性需求，以支持高阶管理人员的决策。

受患者族群结构变化、免疫力缺乏患者增多以及社区和临床环境中真菌感染疾病威胁日益增强的认识等因素驱动，抗真菌药物治疗领域正经历着持续的演变。分子诊断技术的进步、门诊治疗模式的扩展以及监管机构对抗菌药物抗药性的重新关注，正在重塑临床医生选择和使用抗真菌疗法的方式。包括生产者、支付者、医疗服务提供者和经销商在内的价值链各相关人员，必须正确解读这些变化，以优化产品系列和病患用药策略。

诊断技术的突破、治疗方法的创新以及供应和获取管道的重组，正在重塑抗真菌治疗的途径和商业性重点。

在抗真菌药物领域，正在发生多项变革性变化，这些变化正在重新定义竞争优势和临床实践。核酸增幅检查和照护现场抗原检测技术的快速发展，显着提高了诊断准确性，缩短了诊断时间，并使早期标靶治疗成为可能。这种转变减少了经验性频谱药物的使用，并提高了安全性良好、病原体覆盖范围明确的药物的商业性价值。

该评估旨在评估 2025 年关税调整如何重塑抗真菌药物市场所有相关人员的供应链决策、筹资策略和商业规划。

2025年推出的关税政策和贸易措施正在为整个医药供应链带来巨大摩擦，尤其对依赖跨国原料采购和国际製造地的产品影响尤为显着。关税分类和适用税率的变化迫使製造商重新评估其製造地选择、契约製造协议和库存策略，以降低成本波动和交货不确定性。

详细的细分洞察，展示了药物类别、剂型、治疗亚型、分销管道和最终用户如何决定临床效用和商业性策略。

精准了解市场区隔对于协调不同抗真菌药物应用情境下的产品、临床和商业策略至关重要。依药物类别划分，市场大致可分为Allylamines、Azole、棘白菌素类和Polyenes，每类药物都具有独特的药理学特征，影响着药物的采纳策略和合理用药的优先顺序。Allylamines药物在治疗表皮肤疾病方面仍发挥重要作用，而Azole则涵盖了从黏膜皮肤感染疾病到全身性感染疾病的广泛口服治疗。棘白菌素类药物因其杀菌活性和良好的安全性，常用于治疗侵袭性念珠菌症病，而Polyenes在严重和难治性全身感染疾病中继续发挥关键作用，因为在这些感染中，杀菌作用至关重要。

影响美洲、欧洲、中东和非洲以及亚太地区的区域趋势，这些趋势塑造了进入途径、诊断方法的传播和商业策略。

区域趋势对抗真菌药物领域的临床实务模式、监管方法和商业性可行性有显着影响。在美洲，临床指引的采纳和完善的门诊医疗保健体系促使口服Azole被推荐用于治疗多种社区获得性感染，同时，医院也大量处方集棘白菌素类药物治疗侵袭性疾病。该地区先进的诊断基础设施正在加速标标靶治疗的推广应用，并支持以疗效和安全性数据为优先的抗菌倡议。

现有公司的优势、伙伴关係模式和治疗差异化如何驱动抗真菌药物的竞争定位和策略投资？

抗真菌药物领域的竞争动态由老牌巨头、新兴专业公司和策略伙伴关係共同构成，这些因素共同影响着产品的生命週期和市场进入路径。拥有成熟产品系列的老牌厂商利用其临床认可度和与医院的良好关係来维持其在处方集中的地位。同时，新参与企业则致力于透过差异化的作用机制、更高的安全性或更便捷的剂型来取代现有产品。

为製造商提供切实可行的、基于证据的行动，以使临床差异化与具有韧性的价值链、战略伙伴关係以及以支付方为中心的价值提案保持一致。

为了在诊断技术进步、监管力度加大和分销管道变革的背景下取得成功，行业领导者应采取一系列有针对性的倡议，将临床价值与商业性可行性相结合。首先，应在研发计划早期就整合诊断伙伴关係，以便透过临床试验和上市后证据证明标靶治疗时间缩短和患者预后改善。这种合作有助于加强与支付方的对话，并支持符合药品管理原则的准入模式。

采用多方面的研究途径，结合临床文献、相关人员访谈和供应链政策分析，以检验实务见解。

本分析的调查方法结合了对同行评审的临床文献、监管指南和公开政策文件的系统性回顾，以及对临床医生、医院药剂师和行业高管的定性访谈。文献整合优先考虑高品质的资讯来源，重点关注诊断准确性、真菌感染疾病管理的临床指南和抗菌药物管理框架，以确保临床解读基于当代医学实践。

整合临床、营运和商业性需求，以有针对性的证据、灵活的供应策略和伙伴关係主导的商业化为导向。

抗真菌药物市场正处于一个转折点，诊断技术的进步、治疗方法的创新以及不断变化的商业性结构在此交汇，既带来了机会，也带来了挑战。临床进展降低了诊断的不确定性，人们越来越重视那些能够精准覆盖病原体且对易感患者群体具有高安全性的药物。在商业层面，不断变化的经销管道和受价格影响的供应考量，要求企业制定更精细的筹资策略和更灵活的生产计划。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：抗真菌药物市场：依药物类别划分

  • Allylamines基
  • Azole
  • 棘白菌素
  • Polyenes

第九章：抗真菌药物市场（依剂型划分）

  • 胶囊
  • 奶油
  • 软膏
  • 粉末
  • 悬浮液
  • 药片

第十章：抗真菌药物市场：依治疗领域划分

  • 曲菌症
    • 慢性的
    • 侵入性
  • 念珠菌症
    • 口腔和咽
    • 系统
    • 外阴阴道区域
  • 隐球菌病
  • 皮肤丝状菌症
    • 体癣
    • 香港脚

第十一章：抗真菌药物市场：依分销管道划分

  • 离线
  • 在线的

第十二章：抗真菌药物市场：依最终用户划分

  • 诊所
  • 居家医疗
  • 医院

第十三章：抗真菌药物市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：抗真菌药物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：抗真菌药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国抗真菌药物市场

第十七章：中国抗真菌药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • SCYNEXIS, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.
Product Code: MRR-4312A385A460

The Antifungal Drugs Market was valued at USD 16.79 billion in 2025 and is projected to grow to USD 17.81 billion in 2026, with a CAGR of 6.39%, reaching USD 25.93 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.79 billion
Estimated Year [2026] USD 17.81 billion
Forecast Year [2032] USD 25.93 billion
CAGR (%) 6.39%

A strategic framing of the antifungal landscape that synthesizes clinical advances, distribution shifts, and commercial imperatives for executive decision-makers

The antifungal therapeutic landscape is undergoing sustained evolution driven by shifting patient demographics, rising immunocompromised populations, and an elevated awareness of fungal threats in both community and clinical settings. Advances in molecular diagnostics, the expansion of outpatient treatment paradigms, and renewed regulatory focus on antimicrobial resistance together reshape how clinicians select and administer antifungal therapy. Stakeholders across the value chain-including manufacturers, payers, providers, and distributors-must interpret these shifts to optimize product portfolios and patient access strategies.

This executive summary synthesizes contemporary drivers, structural changes, and practical implications for industry participants. It frames the interplay between therapeutic innovation, commercial channels, and regulatory pressures while highlighting where near-term opportunities and operational risks intersect. The report aims to equip executives and strategy teams with a concise, evidence-based orientation that supports investment prioritization, portfolio rationalization, and partnership decisions.

Contextualizing antifungal agents within broader healthcare transformation clarifies where technology, policy, and market behavior converge to influence uptake. As outpatient care expands and digital distribution channels mature, the conventional dynamics of prescribing, dispensing, and adherence are being reconfigured. Consequently, strategic responses must bridge clinical value with commercial accessibility while anticipating changes in reimbursement and supply chain resilience.

How diagnostic breakthroughs, therapeutic innovation, and supply and access reconfigurations are reshaping antifungal care pathways and commercial priorities

The antifungal arena is experiencing several transformative shifts that are redefining competitive advantage and clinical practice. Rapid improvements in diagnostic accuracy-driven by nucleic acid amplification tests and point-of-care antigen detection-are shortening diagnostic windows and enabling earlier, targeted therapy. This transition reduces empirical broad-spectrum use and elevates the commercial importance of agents with favorable safety profiles and clear pathogen coverage.

Concurrently, therapeutic innovation has moved beyond incremental reformulation toward novel mechanisms and optimized dosing strategies for vulnerable populations. Agents that demonstrate strong efficacy against resistant Candida and Aspergillus strains are commanding greater clinical interest, while combination approaches and bioavailability-enhancing delivery systems are extending the relevance of older chemical classes. Regulatory pathways for orphan and fast-track designations have created clearer incentives for investment in treatments for life-threatening fungal infections.

On the commercial side, distribution and procurement practices are shifting as healthcare systems adopt value-based contracting and seek predictable supply arrangements. Manufacturers are responding with differentiated access programs and targeted educational initiatives aimed at antimicrobial stewardship teams. Supply-chain resilience and manufacturing quality assurance are also rising to prominence following recent disruptions, prompting stronger vendor qualification requirements and contingency planning.

Assessing how 2025 tariff adjustments have reshaped supply chain decisions, procurement strategies, and commercial planning across antifungal drug stakeholders

Tariff policy and trade measures introduced in 2025 have created notable friction across pharmaceutical supply chains, with particular implications for products that rely on cross-border raw material sourcing and international manufacturing footprints. Changes in tariff classification and applied rates have prompted manufacturers to reassess manufacturing site selection, contract manufacturing arrangements, and inventory strategies to mitigate cost volatility and delivery uncertainty.

The cumulative effect extends beyond direct cost pressures to influence commercial decisions such as product localization, regional pricing strategies, and contract structuring with distributors. Many organizations have increased emphasis on nearshoring and dual-sourcing arrangements to preserve continuity of supply while insulating margins from transient tariff shocks. This reconfiguration has required updated procurement clauses that incorporate tariff pass-through mechanisms and currency hedging considerations.

Clinicians and hospital pharmacies may experience indirect effects as procurement teams prioritize supply security and predictable lead times. For smaller specialty manufacturers, tariffs have increased the complexity of international launches and elevated the administrative burden of customs compliance. Moving forward, firms are prioritizing scenario-based planning that integrates tariff sensitivity analyses into commercial modeling and regulatory submission strategies to preserve access and protect patient care pathways.

Detailed segmentation insights showing how drug class, dosage forms, therapeutic subtypes, distribution channels, and end users determine clinical utility and commercial tactics

A nuanced understanding of market segmentation is essential to align product, clinical, and commercial strategies across heterogeneous antifungal use cases. When viewed by drug class, the landscape encompasses allylamines, azoles, echinocandins, and polyenes, each presenting distinct pharmacologic profiles that influence formulary positioning and stewardship priorities. Allylamines remain relevant for superficial dermatologic indications, while azoles provide broad oral coverage used across mucocutaneous and systemic infections. Echinocandins are often preferred in invasive candidiasis for their fungicidal activity and favorable safety, and polyenes maintain a role in severe, refractory systemic infections where fungicidal potency is critical.

Dosage form considerations further shape where products compete and how they are delivered to patients. Capsule and tablet formats support outpatient adherence and chronic administration, whereas cream and ointment formulations are central to dermatophytosis management in primary care settings. Powder and suspension preparations offer flexibility for pediatrics and patients with swallowing limitations, while topical and systemic formulations are selected based on infection severity and site.

Therapeutic area segmentation highlights differentiated clinical pathways and decision drivers. Aspergillosis is subdivided into chronic and invasive forms, each requiring distinct diagnostic workflows and therapeutic intensity. Candidiasis presents in oropharyngeal, systemic, and vulvovaginal manifestations that demand tailored dosing regimens and access considerations. Cryptococcosis remains a critical concern in severely immunocompromised populations, whereas dermatophytosis, including tinea corporis and tinea pedis, is often managed in ambulatory and retail settings where rapid symptom relief and user-friendly formulations matter.

Distribution channels are an important strategic axis, spanning offline and online pathways. Offline channels encompass traditional hospital and clinic procurement and retail pharmacy dispensation, while online channels are increasingly relevant for maintenance therapy, OTC antifungal products, and homecare delivery models. End-user segmentation-spanning clinics, homecare settings, and hospitals-further clarifies service design, dosing convenience, and patient support programs required for optimal adherence and outcomes. Together, these segmentation lenses inform targeted product development, differentiated messaging, and channel-specific commercial interventions.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape access pathways, diagnostic adoption, and commercial strategies

Regional dynamics exert a strong influence on clinical practice patterns, regulatory approaches, and commercial viability across the antifungal space. In the Americas, clinical guideline adoption and broad outpatient care ecosystems favor oral azoles for many community-acquired indications and support robust hospital formularies for echinocandins in invasive disease. The region's advanced diagnostic infrastructure accelerates uptake of targeted therapies and supports stewardship initiatives that prioritize efficacy and safety data.

Europe, Middle East & Africa presents a heterogeneous environment where regulatory frameworks, access constraints, and epidemiologic burdens vary significantly. In parts of Europe, centralized reimbursement mechanisms and stringent pricing scrutiny encourage manufacturers to align evidence generation with health-technology assessment expectations. In the Middle East and Africa, limited diagnostic capacity and differing procurement practices can slow the adoption of novel agents, while public health programs prioritize scalable, cost-effective interventions for endemic mycoses.

Asia-Pacific features dynamic market conditions characterized by rapid outpatient care expansion, increasing private-sector participation, and diverse regulatory pathways. Several countries in the region are investing in diagnostic modernization, which in turn enables faster identification of invasive fungal infections and a growing demand for systemic antifungal agents. Supply-chain considerations, local manufacturing incentives, and varying payer structures mean that tailored commercialization strategies are essential for successful regional launches.

Across all regions, cross-border partnerships, technology transfer arrangements, and regional clinical collaborations are becoming more common as manufacturers seek to harmonize evidence generation and accelerate patient access while managing regulatory complexity.

How incumbent strengths, partnership models, and therapeutic differentiation drive competitive positioning and strategic investment in antifungal therapeutics

Competitive dynamics in the antifungal sector reflect a blend of legacy incumbents, emerging specialty players, and strategic partnerships that collectively shape product life cycles and market access trajectories. Incumbent manufacturers with established portfolios leverage clinical familiarity and hospital relationships to sustain formulary positions, while newer entrants focus on differentiated mechanisms, improved safety profiles, or convenient delivery formats to displace entrenched options.

Strategic alliances between pharmaceutical companies and diagnostic firms are increasingly important, creating bundled propositions that pair rapid identification with targeted therapy. Such collaborations can accelerate uptake by shortening time-to-appropriate treatment and reducing the clinical uncertainty that often drives broad-spectrum empirical use. In parallel, contract manufacturing organizations and regional production hubs are forming value-based partnerships with brand owners to improve supply resilience and manage cost bases.

Investor interest and M&A activity tend to concentrate on assets addressing resistant pathogens, novel oral formulations for systemic disease, and technologies enabling outpatient adherence. Clinical development pipelines emphasize agents active against azole- and echinocandin-resistant strains, as well as reformulations that expand indications or improve pharmacokinetics. Companies that can demonstrate robust real-world evidence and health-economic impact will be better positioned to negotiate favorable reimbursement and formulary placement.

Practical, evidence-driven actions for manufacturers to align clinical differentiation with resilient supply chains, strategic partnerships, and payer-focused value propositions

To thrive amid diagnostic advances, regulatory scrutiny, and distribution evolution, industry leaders should adopt a set of targeted actions that align clinical value with commercial execution. First, integrate diagnostic partnerships early in development plans to ensure that clinical trials and post-market evidence demonstrate actionable improvements in time-to-targeted therapy and patient outcomes. This linkage will strengthen payer conversations and support stewardship-aligned access models.

Second, diversify manufacturing and supply strategies to mitigate tariff and trade risks by exploring nearshoring, dual sourcing, and flexible contract manufacturing agreements. Embedding tariff sensitivity into commercial scenario planning will reduce the likelihood of disruption and preserve access in critical care settings. Third, tailor go-to-market approaches by segmenting opportunities across drug class, dosage form, therapeutic indication, distribution channel, and end-user context. Products intended for dermatologic outpatient care should emphasize ease of use and retail availability, while systemic agents for invasive disease require hospital-level engagement and robust safety monitoring programs.

Finally, invest in real-world evidence generation and health economic modeling that directly addresses payer priorities and formulary decision criteria. Operationalize these data through stakeholder education, stewardship collaborations, and value-based contracting pilots that demonstrate measurable reductions in length of stay, readmissions, or downstream antifungal utilization. These steps will help translate clinical differentiation into sustainable commercial advantage.

A multi-method research approach combining clinical literature synthesis, stakeholder interviews, and supply chain policy analysis to validate actionable insights

The research methodology underpinning this analysis combined a structured review of peer-reviewed clinical literature, regulatory guidance, and publicly available policy documents with primary qualitative interviews of clinicians, hospital pharmacists, and industry executives. Literature synthesis prioritized high-quality sources focused on diagnostic accuracy, clinical guidelines for fungal disease management, and stewardship frameworks to ensure the clinical interpretations are grounded in contemporary practice.

Primary research included semi-structured interviews designed to uncover practical decision criteria used by formulary committees, procurement teams, and frontline prescribers. Interview insights were triangulated with secondary evidence to validate recurring themes and to surface regional and end-user nuances. The methodology also incorporated a review of trade and customs policy changes that could affect pharmaceutical supply chains, coupled with scenario analysis to illustrate potential operational responses.

Limitations include the variability of regional data granularity and the evolving nature of tariff and regulatory environments; where primary data were limited, findings emphasize directional implications rather than definitive causal claims. The research adhered to rigorous data validation practices, including cross-verification of interview summaries with source documents and anonymized confirmation from multiple stakeholders when feasible.

Synthesis of clinical, operational, and commercial imperatives that point to targeted evidence, agile supply strategies, and partnership-driven commercialization

The antifungal market is at an inflection point where diagnostic progress, therapeutic innovation, and shifting commercial constructs converge to create both opportunity and complexity. Clinical advances reduce diagnostic uncertainty and favor agents that can demonstrate precise pathogen coverage and strong safety in vulnerable cohorts. Commercially, distribution channel evolution and tariff-driven supply considerations require more sophisticated procurement strategies and agile manufacturing planning.

For manufacturers and stakeholders, success will hinge on aligning product design with the realities of channel dynamics and end-user needs. This means pairing clinical differentiation with accessible dosing formats for outpatient care, creating bundled diagnostic-therapeutic propositions to streamline decision-making, and investing in real-world evidence that addresses payer and stewardship priorities. Organizational resilience will also depend on proactive supply-chain reconfiguration and the capacity to adapt contracting approaches in response to policy shifts.

Taken together, these dynamics suggest a strategic path that emphasizes targeted evidence generation, flexible operational models, and partnership-driven commercialization. Firms that execute on these dimensions will be better positioned to deliver sustained clinical value and capture enduring commercial traction in an environment of rising complexity and heightened stakeholder expectations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antifungal Drugs Market, by Drug Class

  • 8.1. Allylamines
  • 8.2. Azoles
  • 8.3. Echinocandins
  • 8.4. Polyenes

9. Antifungal Drugs Market, by Dosage Form

  • 9.1. Capsule
  • 9.2. Cream
  • 9.3. Ointment
  • 9.4. Powder
  • 9.5. Suspension
  • 9.6. Tablet

10. Antifungal Drugs Market, by Therapeutic Area

  • 10.1. Aspergillosis
    • 10.1.1. Chronic
    • 10.1.2. Invasive
  • 10.2. Candidiasis
    • 10.2.1. Oropharyngeal
    • 10.2.2. Systemic
    • 10.2.3. Vulvovaginal
  • 10.3. Cryptococcosis
  • 10.4. Dermatophytosis
    • 10.4.1. Tinea Corporis
    • 10.4.2. Tinea Pedis

11. Antifungal Drugs Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Antifungal Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Homecare
  • 12.3. Hospitals

13. Antifungal Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antifungal Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antifungal Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Antifungal Drugs Market

17. China Antifungal Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Astellas Pharma Inc.
  • 18.6. Basilea Pharmaceutica Ltd.
  • 18.7. Bayer AG
  • 18.8. Cipla Limited
  • 18.9. Dr. Reddy's Laboratories Ltd.
  • 18.10. Gilead Sciences, Inc.
  • 18.11. GlaxoSmithKline plc
  • 18.12. Glenmark Pharmaceuticals Limited
  • 18.13. Hikma Pharmaceuticals PLC
  • 18.14. Johnson & Johnson
  • 18.15. Merck & Co., Inc.
  • 18.16. Mycovia Pharmaceuticals, Inc.
  • 18.17. Novartis AG
  • 18.18. Pfizer Inc.
  • 18.19. Sanofi S.A.
  • 18.20. SCYNEXIS, Inc.
  • 18.21. Sun Pharmaceutical Industries Ltd.
  • 18.22. Teva Pharmaceutical Industries Ltd.
  • 18.23. Viatris Inc.
  • 18.24. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIFUNGAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIFUNGAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OROPHARYNGEAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OROPHARYNGEAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OROPHARYNGEAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY VULVOVAGINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY VULVOVAGINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY VULVOVAGINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CRYPTOCOCCOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CRYPTOCOCCOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TINEA CORPORIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TINEA CORPORIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TINEA CORPORIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TINEA PEDIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TINEA PEDIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TINEA PEDIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 204. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 210. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 213. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 214. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)